Philip Morris International posted second-quarter 2026 results that exceeded Wall Street expectations across every major metric, extending the company's streak of earnings beats and reinforcing the investment thesis that its transition away from traditional cigarettes toward smoke-free products is generating durable margin and revenue growth. Non-GAAP earnings per share reached $2.20 for the quarter, surpassing the $2.04 consensus estimate by $0.16, while revenue came in at $11.19 billion, beating predictions by approximately $580 million.
The headline revenue figure represented organic growth of 7.6%, driven by contributions from both the smoke-free and combustibles segments. Smoke-free products, led by the IQOS heated tobacco platform and complemented by the ZYN oral nicotine brand and VEEV e-vapor line, generated organic revenue growth of 9.7% and now account for approximately 42% of the company's total net revenues, up half a percentage point from a year earlier. PMI smoke-free products are now available in 109 markets globally.
Gross profit increased 11.5% on a reported basis, with margin expansion reflecting strong pricing power, scale benefits, and a favorable shift toward higher-margin smoke-free products. Operating income rose 22.0% on a reported basis and 10.7% organically, outpacing the revenue growth rate and demonstrating the operating leverage embedded in the company's distribution-heavy international business model.
Management set third-quarter 2026 EPS guidance in a range of $2.20 to $2.25 per share, slightly above current sell-side estimates, a signal that the company expects the momentum visible in the second quarter to continue through the back half of the year. Investors welcomed the update: shares of PM opened near $188.03 on Wednesday, approaching the 52-week high of $194.90 and extending a year-to-date advance that has made the stock one of the more consistent outperformers in the consumer staples sector.
Reported diluted EPS of $1.80 was below the adjusted figure due to a non-cash impairment charge tied to PMI's equity investment in RBH, the Canadian tobacco subsidiary. Excluding that item, the underlying earnings trajectory was described by management as reflecting the strongest broad-based momentum in several quarters, supported by the continued global rollout of IQOS and the maturation of the ZYN brand in markets outside the United States following the resolution of US Food and Drug Administration authorization questions last year.
One area investors will monitor closely in the coming quarters is the pace of IQOS market share gains in Japan, where the company noted that in-market sales growth had moderated temporarily following excise-driven pricing actions. Japan remains IQOS's largest and most profitable single market, and any sustained slowdown there would be a meaningful headwind to the overall smoke-free revenue trajectory. Management expressed confidence that the Japan moderation is temporary and tied specifically to the excise timing, rather than a structural shift in consumer demand for heated tobacco products.
Tobacco sector peers, including Altria and Reynolds American parent British American Tobacco, were each up modestly in early trading as the Philip Morris beat lifted sentiment across the category. The results provide a rare bright spot on a macro calendar dominated by geopolitical uncertainty and rising oil prices, and position PM shares as a potential defensive anchor in portfolios navigating an environment of elevated market volatility.